Co-Administration of LDX (SPD489) and Venlafaxine XR (EFFEXOR XR) in Healthy Volunteers

Study Description

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Brief Summary:

This study will examine the effects of co-administration of SPD489 and the antidepressant EFFEXOR XR on the pharmacokinetics of lisdexamfetamine, d-amphetamine, and EFFEXOR XR. In addition, serial blood pressure and pulse measures will be obtained and examined to ensure that there are no unexpected changes in vital signs following co administration of SPD489 and EFFEXOR XR that would impact the further study of this drug combination. The hypothesis is that a drug drug interaction could possibly exist.

Condition or disease	Intervention/treatment	Phase
Healthy	Drug: LDX + Venlafaxine XR; Drug: Venlafaxine XR + LDX	Phase 1

Study Design

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Study Type :	Interventional (Clinical Trial)
Actual Enrollment :	80 participants
Allocation:	Randomized
Intervention Model:	Parallel Assignment
Masking:	None (Open Label)
Primary Purpose:	Treatment
Official Title:	A Phase 1, Open-label, Drug Interaction Study Evaluating the Pharmacokinetic Profiles of SPD489 and EFFEXOR XR, Administered Alone and in Combination in Healthy Adult Subjects
Study Start Date :	November 2010
Actual Primary Completion Date :	December 2010
Actual Study Completion Date :	January 2011

Arms and Interventions

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm	Intervention/treatment
Experimental: LDX (SPD489) + Venlafaxine XR (Effexor XR)	Drug: LDX + Venlafaxine XR; Day 1-5 LDX 30mg; Day 6-10 LDX 50mg; Day 11-15 LDX 70mg; Day 16-20 LDX 70mg and Venlafaxine XR 75mg daily; Day 21-25 LDX 70mg and Venlafaxine XR 150mg daily; Day 26-30 LDX 70mg and Venlafaxine XR 225mg daily; Day 31-34 Venlafaxine XR 150mg daily; Day 35-38 Venlafaxine XR 75mg daily.; Other Name: Lisdexamfetamine dimesylate, LDX, Vyvanse, SPD489; Venlafaxine hydrochloride extended-release, Effexor XR,
Experimental: Venlafaxine XR + LDX	Drug: Venlafaxine XR + LDX; Day 1-5 Venlafaxine XR 75mg; Day 6-10 Venlafaxine XR 150mg; Day 11-15 Venlafaxine XR 225mg; Day 16-20 Venlafaxine XR 225mg and LDX 30mg daily; Day 21-25 Venlafaxine XR and LDX 50mg daily; Day 26-30 Venlafaxine XR 225mg and LDX 70mg daily; Day 31-34 Venlafaxine XR 150mg; Day 35-38 Venlafaxine XR 75mg.; Other Name: Venlafaxine hydrochloride extended-release, Effexor XR; Lisdexamfetamine dimesylate, LDX, Vyvanse, SPD489

Outcome Measures

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :

1. Maximum Plasma Concentration (Cmax) of Lisdexamfetamine Dimesylate [ Time Frame: Day 15 and Day 30 (24 hour sampling) ]
   Lisdexamfetamine dimesylate (SPD489) itself is inactive, but following oral administration is converted to the active isomer, d-amphetamine, that is responsible for the drug's therapeutic activity.
2. Cmax of d-Amphetamine [ Time Frame: Day 15 and Day 30 (24 hour sampling) ]
   d-Amphetamine is the active isomer of Lisdexamfetamine dimesylate (SPD489) and is responsible for the drug's therapeutic activity.
3. Cmax of Venlafaxine Hydrochloride [ Time Frame: Day 15 and Day 30 (24 hour sampling) ]
   Venlafaxine Hydrochloride is the active ingredient of Effexor XR
4. Cmax of o-Desmethylvenlafaxine [ Time Frame: Day 15 and Day 30 (24 hour sampling) ]
   Venlafaxine, after oral administration, is metabolized in the liver to an active metabolite, o-Desmethylvenlafaxine.
5. Cmax of Composite (Venlafaxine + o-Desmethylvenlafaxine) [ Time Frame: Day 15 and Day 30 (24 hour sampling) ]
6. Area Under the Steady-state Plasma Concentration-time Curve (AUC) of Lisdexamfetamine Dimesylate [ Time Frame: Day 15 and Day 30 (24 hour sampling) ]
7. AUC of d-Amphetamine [ Time Frame: Day 15 and Day 30 (24 hour sampling) ]
8. AUC of Venlafaxine Hydrochloride [ Time Frame: Day 15 and Day 30 (24 hour sampling) ]
9. AUC of o-Desmethylvenlafaxine [ Time Frame: Day 15 and Day 30 (24 hour sampling) ]
10. AUC of Composite (Venlafaxine + o-Desmethylvenlafaxine) [ Time Frame: Day 15 and Day 30 (24 hour sampling) ]
11. Time of Maximum Plasma Concentration (Tmax) of Lisdexamfetamine Dimesylate [ Time Frame: Day 15 and Day 30 (24 hour sampling) ]
12. Tmax of d-Amphetamine [ Time Frame: Day 15 and Day 30 (24 hour sampling) ]
13. Tmax of Venlafaxine Hydrochloride [ Time Frame: Day 15 and Day 30 (24 hour sampling) ]
14. Tmax of o-Desmethylvenlafaxine [ Time Frame: Day 15 and Day 30 (24 hour sampling) ]
15. Tmax of Composite (Venlafaxine + o-Desmethylvenlafaxine) [ Time Frame: Day 15 and Day 30 (24 hour sampling) ]

Secondary Outcome Measures :

1. Systolic Blood Pressure [ Time Frame: Baseline and up to 39 days ]
2. Diastolic Blood Pressure [ Time Frame: Baseline and up to 39 days ]
3. Pulse Rate [ Time Frame: Baseline and up to 39 days ]

Eligibility Criteria

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Ages Eligible for Study:	18 Years to 45 Years (Adult)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	Yes

Criteria

Inclusion Criteria:

1. Age 18-45 years

2. Subject is willing to comply with any applicable contraceptive requirements of the protocol and is:

   • Male, or
   • Non-pregnant, non-lactating female
   • Females must be at least 90 days post partum or nulliparous.
3. Female subjects must have a negative serum beta Human Chorionic Gonadotropin (HCG) pregnancy test
4. Satisfactory medical assessment
5. Ability to provide information on family history of hypertension.
6. Body Mass Index (BMI) between 18.5 and 30.0kg/m² inclusive.
7. Ability to swallow all investigational products.

Exclusion Criteria:

1. Current or recurrent disease (e.g., cardiovascular, renal, liver, gastrointestinal, malignancy or other conditions)
2. Current or relevant previous history of physical or psychiatric illness.
3. Significant illness.
4. History of significant anxiety, tension, or agitation as assessed by the Investigator.
5. History of or current diagnosis of glaucoma.
6. History of a seizure disorder (other than infantile febrile seizures), any tic disorder or a current diagnosis and/or known family history of Tourette's Disorder.
7. History of symptomatic cardiovascular disease, advanced arteriosclerosis, structural cardiac abnormality, cardiomyopathy, serious heart rhythm abnormalities, coronary artery disease, transient ischemic attack or stroke, or other serious cardiac problems.
8. History of controlled or uncontrolled hypertension or a resting sitting systolic BP >139mmHg or diastolic BP >89mmHg.
9. Known family history of sudden cardiac death or ventricular arrhythmia.
10. Suicidal ideation or any lifetime history of suicidal behavior.
11. Consumption of alcohol, Seville oranges, grapefruit, or any grapefruit containing products within 7 days of first dose of investigational product.
12. Current use of any medication (including prescription, over the counter [OTC], herbal or homeopathic preparations or supplements) with the exception of the occasional dose of acetaminophen, or hormonal contraceptives.
13. History of alcohol or other substance abuse within the last year.
14. A positive screen for alcohol or drugs of abuse.
15. Male subjects who consume more than 21 units of alcohol per week or 3 units per day. Female subjects who consume more than 14 units of alcohol per week or 2 units per day. [1 alcohol unit =1 beer = 1 wine (5oz) = 1 liquor (1.5oz) = 0.75oz alcohol]
16. A positive human immunodeficiency virus (HIV) antibody screen, Hepatitis B surface antigen (HBsAg), or Hepatitis C virus (HCV) antibody screen.
17. Use of tobacco in any form (e.g., smoking or chewing) or other nicotine-containing products in any form (e.g. gum, patch). Ex-users must report that they have stopped using tobacco for at least 30 days prior to receiving the first dose of investigational product.
18. Routine consumption of more than 2 units of caffeine per day or subjects who experience caffeine withdrawal headaches. (One caffeine unit is contained in the following items: one 6oz. cup of coffee, two 12oz. cans of cola, one 12oz. cup of tea, three 1oz. chocolate bars, or one 8oz. serving of an energy drink. Decaffeinated coffee, tea, or cola are not considered to contain caffeine).
19. Donation of blood or blood products (e.g., plasma or platelets) within 60 days prior to receiving the first dose of investigational product.

Contacts and Locations

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Locations

United States, Florida
Clinical Pharmacology of Miami
Miami, Florida, United States, 33014

Sponsors and Collaborators

Shire

More Information

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Additional Information:

FDA Recall Information 

Publications of Results:

Ermer J, Haffey MB, Richards C, Lasseter K, Roesch B, Purkayastha J, Corcoran M, Harlin B, Martin P. An open-label investigation of the pharmacokinetic profiles of lisdexamfetamine dimesylate and venlafaxine extended-release, administered alone and in combination, in healthy adults. Clin Drug Investig. 2013 Apr;33(4):243-54. doi: 10.1007/s40261-013-0073-1.

Responsible Party:	Shire
ClinicalTrials.gov Identifier:	NCT01235338 History of Changes
Other Study ID Numbers:	SPD489-117
First Posted:	November 5, 2010
Results First Posted:	December 8, 2011
Last Update Posted:	April 4, 2013
Last Verified:	March 2013

Additional relevant MeSH terms:

Venlafaxine Hydrochloride; Lisdexamfetamine Dimesylate; Serotonin and Noradrenaline Reuptake Inhibitors; Neurotransmitter Uptake Inhibitors; Membrane Transport Modulators; Molecular Mechanisms of Pharmacological Action; Neurotransmitter Agents	Physiological Effects of Drugs; Antidepressive Agents, Second-Generation; Antidepressive Agents; Psychotropic Drugs; Central Nervous System Stimulants; Dopamine Uptake Inhibitors; Dopamine Agents